LDX

3.33%

3.1¢ lumos diagnostics holdings limited

Ann: FDA Decision for FebriDx, page-81

First 81 Last

Share
Profile

Follow
LongTony

2,636 Posts.

2385

25/10/23

21:45

Post #: 70539814
Share

Originally posted by LongTony: ↑

I think this is the report from the FDA around their review (approval) of the MeMed BV test. The development of the test was partly funded by the US government.

https://www.accessdata.fda.gov/cdrh_docs/reviews/K210254.pdf

At the top of page 4 of the report they outline the results you get from the "machine that goes 'bing!'" 15 minutes after the sample is taken - the text is pasted as an image below. Apparently, according to the review, the test is very reliable and repeatable. However, it's very equivocal when it comes to viral/bacterial/nothing diagnosis, in fact so equivocal to my mind that IMHO it is useless!

As you can see with the score ranges, the MeMed test really creates very little certainty around what to do. A physician or other health professional can run the test, everybody pockets their rebates and they can then prescribe antibiotics for any score from 35 to 100, or maybe even even between 10 to 100. Who knows? And it takes so long (ie 15 minutes, which is longer than a standard appointment) that they'll only do the test if they really have to.

It's a win-win-win! The physician can say they've been diligent, the physician gets extra money, MeMed gets money, and the physician can still prescribe just as many antibiotics as ever, so pharma still gets their money.

When I first had the opportunity to invest in this, I asked Sam if the "industry" in the US was ready for FebriDx and he said the feedback was yes. But looking at the approval for MeMed BV and the knock-back of FebriDx, I'd say it's clear that they're not ready for a line on a piece of paper that says "Don't prescribe $4B US a year in un-necessary antibiotics."

I'd say there's still a big push needed to get the FDA, with its impure architecture, to approve FebriDx, because FebriDx puts a clear line through $4B of Pharma revenue, and although the US says they want to stop, their are too many people riding on that gravy train.

Expand

Reference to my own post sorry!

It contains a brief overview and my assessment of the direct competitor test (MeMed) that was used as the reasoning for rejecting FDA approval back in 2022.

LDX Price at posting: 7.8¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

RCE

Recce's R327 found effective against E.coli during clinical trial

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Microcap Wrap: 5 explorers with news out today

First 81 Last

Add LDX (ASX) to my watchlist

(20min delay)
Last 3.1¢		Change 0.001(3.33%)		Mkt cap ! $14.92M

Open	High	Low	Value	Volume
3.0¢	3.2¢	3.0¢	$59.53K	1.912M

Buyers (Bids)

No.	Vol.	Price($)
5	1117600	3.0¢

Sellers (Offers)

Price($)	Vol.	No.
3.2¢	490000	4

View Market Depth

No.	Vol.	Price($)
3	251333	0.030
2	334500	0.029
13	820202	0.028
2	188779	0.027
2	71568	0.026

Price($)	Vol.	No.
0.032	490000	4
0.033	172001	2
0.034	384518	3
0.035	148000	2
0.036	527000	2

Last trade - 16.10pm 28/06/2024 (20 minute delay)

LDX (ASX) Chart

Ann: FDA Decision for FebriDx, page-81

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Recce's R327 found effective against E.coli during clinical trial

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Ava Risk Group expands US presence with A$0.7M Substation Deal

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Microcap Wrap: 5 explorers with news out today

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: FDA Decision for FebriDx, page-81

Top Stories

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Recce's R327 found effective against E.coli during clinical trial

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Ava Risk Group expands US presence with A$0.7M Substation Deal

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Microcap Wrap: 5 explorers with news out today

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News